Medtronic has reported late-breaking data from the randomised Evolut Low Risk Trial’s five-year outcomes of the Evolut ...

Medtronic has released the two-year results from the clinical trial comparing its Evolut system to Edwards Lifesciences’ SAPIEN system. The Evolut system showed significantly less bioprosthetic ...

1,414 patients were randomized, with 730 receiving TAVR with either a Medtronic Evolut R, PRO, or CoreValve™ and 684 undergoing surgery. "Results at five years support Evolut's supra-annular ...

Medtronic, Abbott and Boston Scientific had updates on their devices used in heart valve disease treatment at the event.

Medtronic (MDT) announced late-breaking data on five-year outcomes from the Evolut Low Risk Trial. Data shows, versus surgery, the Evolut transcatheter aortic valve replacement, TAVR, system ...

The clinic data shows that Evolut TAVR continues to exhibit less bioprosthetic valve dysfunction compared to Edwards Lifesciences’ (EW) SAPIEN TAVR product. I think Medtronic has already made ...

Researchers conducted a post hoc analysis to compare the valve performances between patients with symptomatic severe aortic stenosis who underwent CoreValve or Evolut TAVI with Medtronic devices ...

Medtronic Evolut TAVR system shows durable clinical outcomes and outstanding valve performance at five years in low-risk aortic stenosis patients: Galway, Ireland Tuesday, April 1 ...

GALWAY, Ireland and CHICAGO, March 30, 2025 /PRNewswire/ -- Medtronic plc (MDT), a global leader in healthcare technology, today announced late-breaking data on five-year outcomes from the Evolut ...

vice president and chief medical officer of Structural Heart, which is part of the Medtronic Cardiovascular Portfolio. "These results reinforce the recently reported Evolut evidence from the SMART ...